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Abstract 
Lipoproteins are essential systemic lipid transport particles, composed of apolipoproteins 
embedded in a phospholipid and cholesterol monolayer surrounding a cargo of diverse lipid species.   
Many of the lipids present are susceptible to oxidative damage by lipid peroxidation, giving rise to 
the formation of reactive lipid peroxidation products (rLPPs). In view of the close proximity of the 
protein and lipid moieties within lipoproteins, the probability of adduct formation between rLPPs 
and amino acid residues of the proteins, a process called lipoxidation, is high. There has been 
interest for many years in the biological effects of such modifications, but the field has been limited 
to some extent by the availability of methods to determine the sites and exact nature of such 
modification. More recently, the availability of a wide range of antibodies to lipoxidation products, 
as well as advances in analytical techniques such as liquid chromatography tandem mass 
spectrometry (LC-MSMS), have increased our knowledge substantially. While most work has focused 
on LDL, oxidation of which has long been associated with pro-inflammatory responses and 
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atherosclerosis, some studies on HDL, VLDL and Lipoprotein(a) have also been reported.  As the 
broader topic of LDL oxidation has been reviewed previously, this review focuses on lipoxidative 
modifications of lipoproteins, from the historical background through to recent advances in the field. 
We consider the main methods of analysis for detecting rLPP adducts on apolipoproteins, including 
their advantages and disadvantages, as well as the biological effects of lipoxidized lipoproteins and 
their potential roles in diseases. 
Graphical Abstract: 
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Abbreviations 
AGEs, advanced glycation end products; ALEs, advanced lipoxidation end products; Apo, 
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hydroxy-trans-2-nonenal; HOCl, hypochlorous acid; HPNE, 4-hydroperoxy-trans-2-nonenal; IDL, 
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assisted laser desorption ionization time of flight; MDA, malondialdehyde; MS, mass spectrometry; 
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phosphocholine; POVPC, 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphorylcholine; rLPPs, 
reactive lipid peroxidation products; TBArS, thiobarbituric acid reactive substances; TNBS, 2,4,6-
trinitrobenzene sulfonic acid; VLDL, very low density lipoprotein.  
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1. Introduction to lipoproteins and lipid oxidation 
Lipoproteins are a family of complex particles consisting of amphipathic apolipoproteins 
that carry a wide range of lipids, and therefore have important physiological functions in systemic 
lipid transport. The basic structure is a shell formed of a monolayer of phospholipids and free 
cholesterol surrounding a core of cholesteryl esters and triglycerides [1], with one or more proteins 
associated with the surface phospholipids and partially embedded in the hydrophobic lipid core. The 
role of the proteins is thus to solubilize and stabilize the lipoproteins in an aqueous environment 
such as plasma, which is a major location of lipoproteins. Lipoproteins are classified according to 
their size and density, which is determined by the ratio of protein to lipid, and therefore depends on 
the lipid and apolipoprotein composition. The plasma lipoproteins are typically divided into 7 
classes, which are chylomicrons, chylomicron remnants, VLDL, IDL, LDL, HDL, and Lp(a). The 
chylomicrons are responsible for transport of dietary lipids from the intestine to lipid-metabolizing 
tissues muscle and adipose, and the resulting chylomicron remnants deliver remaining lipid to the 
liver. VLDL, IDL, LDL are involved in the second phase of triglyceride and cholesterol delivery from 
the liver to peripheral tissues, whereas HDL particles are responsible for reverse cholesterol 
transport from cells in the peripheral tissues to the liver to lipoproteins of the endogenous pathway. 
The functions and activities of the lipoprotein particles are largely determined by the combination of 
apolipoproteins they contain, which direct their interaction with receptors as well as containing a 
variety of enzymatic activities.  The lipid cargo is very diverse, and in addition of several classes of 
phospholipid, cholesterol and cholesteryl esters, it can include free fatty acids, sphingolipids, 
ceramides, and sulfolipids [2].  
Many of the components of lipoproteins are susceptible to oxidative damage by free radicals 
of non-radical oxidants, and this has been an energetic field of study since pioneering studies in the 
1980s demonstrated that oxidation of LDL contributed to changes in its biological properties [3–5] as 
described in section 4.  Lipids containing unsaturated fatty acyl chains (especially poly-unsaturated 
ones) can be peroxidized following hydrogen abstraction by radical attack and subsequent addition 
of di-oxygen; the downstream reactions are complex and lead to a plethora of short- and long-chain 
oxidation products; this topic has been extensively reviewed previously [6–9]. Peroxidation at bis-
allylic sites in the fatty acyl chains tends to result in cleavage of the hydrocarbon backbone by Hock 
rearrangement or other mechanisms, resulting in formation of an aldehyde on one or both chains 
[10]. Intrachain cyclization reactions can also occur, for example leading to formation of 
isoprostanes or isolevuglandins. Secondary radical attack and addition of oxygen can occur at other 
sites, resulting in complex structures with multiple reactive groups including aldehydes, ketones, 
epoxides and cyclopentenone rings.  A common motif that rises following cleavage is the -
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substituted -alkenal, as in 4-hydroxynonenal (HNE) or 4-oxo-nonenal, although a variety of 
analogous structures are possible [6,8,11]. The headgroups of amine-containing phospholipids, e.g 
phosphatidylserine, can be modified by oxidative deamination, which also generates an aldehyde 
[12].  Alternatively, unsaturated lipids can be attacked by electrophilic agents such as hypochlorous 
acid (HOCl), which causes the formation of chlorohydrins (hydroxyl and chlorine groups on adjacent 
carbons) on fatty acyl chains, or cleavage of the vinyl ether bonds of plasmalogens to yield chloro-
aldehydes. Radical nitrogen species such as nitrogen dioxide can cause peroxidation via hydrogen 
abstraction, but may also undergo addition reactions leading to nitrated or nitrosylated fatty acyl 
chains, some of which also contain motifs similar to the substituted alkenals mentioned above. The 
key point about lipid oxidation products containing aldehydes, ketones, epoxides and substituted 
alkenals is that they are electrophilic and moderately to highly reactive with nucleophilic groups, 
which endows them with unusual properties through the ability to react with biological. While 
several different collective names for such compounds exist, in this review we have used the term 
“reactive lipid peroxidation products”, or rLPPs. Figure 1 shows the structure of the various rLPPs 
discussed in this review. 
Lipid oxidation in lipoproteins has been extensively investigated and the reader is directed 
to reviews on this topic for more detail [13,14]. Consequently, lipid oxidation is not the main focus of 
this review, which instead addresses the more specific issue of how the protein moieties of 
lipoproteins are modified by the resulting rLPPs, a process known as lipoxidation and explained in 
more detail in Section 2. In view of the close proximity of protein and lipids within lipoprotein, the 
probability of adduct formation between rLPPs and residues of the proteins is relatively high, but to 
date no lipoprotein reviews have focused specifically on lipoxidation, despite the fact that there is 
growing awareness of the signaling importance of this modification [15–18]. This review addresses 
mainly HDL and LDL lipoxidation, as the majority of research has investigated these lipoproteins, and 
aims to provide a concise overview of lipoprotein modification by oxidized lipid adducts from early 
pioneering studies to recent advances in molecular knowledge. 
 
2. Protein oxidation and lipoxidation 
In parallel to lipid oxidation, the apoprotein moieties of lipoproteins can also be oxidized 
directly by a range of oxidants; usually the basic side chains (lysine, arginine and histidine), and 
sidechains containing sulfur (cysteine, methionine) or aromatic groups (tyrosine, tryptophan, 
phenyalanine) are most readily modified. Several studies have investigated the relative susceptibility 
of lipoprotein residues to oxidants, both in vitro and ex-vivo, in an attempt to identify markers of 
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damage as well as to understand changes in lipoprotein function [19–22]. Nucleophilic sidechains, 
i.e. those containing amine or thiol groups, can also be modified by reaction with rLPPs. Protein 
lipoxidation can occur by one of two chemical reactions: Michael addition occurs when the 
electrophilic β-carbon of a reactive lipid oxidation product reacts with the amino group of histidine 
and lysine or the thiol group of a cysteine; Schiff’s base formation involves reaction of the free 
amino group of a lysine, arginine or N-terminal amine with the carbonyl group of an aldehyde or 
ketone. Schiff’s base adducts are less stable than Michael adducts, and both are potentially 
reversible depending on the chemical environment.  Moreover, depending on the electrophilic 
species involved, secondary reactions such as cyclization, dehydration, oxidation, or condensation 
with an additional electrophile may take place, leading to formation of more stable adducts that are 
referred to as advanced lipoxidation end products, or ALEs, by analogy with the better-known 
advanced glycation end products (AGEs). For example, the HNE Michael adducts tend to cyclize to 
hemiacetals, which the HNE Schiff’s base with lysine can generate a stable 2-pentylpyrrole derivative 
(Jacobs and Sayre, 2010); the Michael adduct of acrolein can rearrange to form formyl-
dehydropiperidino lysine (FDP-lysine) (Colzani, 2013 J Prot). The process of lipoxidation has been 
very well explained previously (Sayre 2006; Jacobs and Sayre 2010; Parvez 2018), and consequently 
will not be covered in depth here, although the structures most commonly discussed in the review 
are shown in Figure 2.  
Many approaches have been used to study lipoprotein oxidation and lipoxidation [10,16,23]. 
The ultimate goal is to be able to detect and identify lipoxidation under physiological conditions and 
in biological or clinical samples, but many studies of modification in vitro have been carried out as a 
stepping stone to this stage, to develop methodology or establish the most likely products. Oxidation 
of lipoproteins in vitro is often achieved by treatment with transition metal ions, mostly commonly 
Cu2+, but occasionally Fe2+ in combination with hydrogen peroxide as a Fenton reagent to generate 
hydroxyl radicals is used. The use of iron also represents a model for ferretin-induced oxidation of 
LDL. Other methods for oxidation of lipoproteins include radical initiators, such as 2,2′-Azobis(2-
methylpropionamidine) dihydrochloride (AAPH), or treatment with UV light. These are all able to 
initiate lipid peroxidation, and therefore lead to lipoxidation of the apolipoprotein. More 
physiological approaches include enzymes such as lipoxygenases and cytochrome P450 enzymes, 
which catalyse radical oxidations and hydroxylations of fatty acids, or myeloperoxidase, which is 
well-known for its ability to generate hypohalous acids such as HOCl, but is also able to catalyse 
direct oxidations of some substrates [24].  There have also been many studies in vitro where 
lipoproteins, especially LDL, have been modified by direct treatment with reactive lipid peroxidation 
products; most work has been carried out with small unsaturated aldehydes, such as acrolein, 
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malondialdehyde (MDA) and HNE, but a small number of studies with less well-known rLPPs and 
even esterified oxidized phospholipids have been reported, as described in the following sections.  
 
3. Approaches to the analysis of LDL and HDL lipoxidation 
The analysis of LDL and HDL is dependent on the separation of these lipoproteins from 
whole plasma. A common method for separation of these particles is by gradient ultracentrifugation. 
Using different salt concentrations and centrifugation at high g-forces, the lipoproteins of different 
density migrate in the gradient, allowing their separation and forming bands that can be collected 
and analysed further. This methodology, which dates back to 1955, was developed by Havel et al. 
[25] and has been used extensively for the study of lipoproteins [26,27]. There are other methods 
that take advantage of different characteristics of lipoprotein particles for their separation, such as 
size exclusion chromatography, which depends on the size difference between the lipoproteins, and 
gradient gel electrophoresis, which uses both size and charge for its separation [26,28,29].   
All the studies included in this review used a form of the gradient ultracentrifugation 
method to separate lipoproteins, followed by the analysis of oxidized lipoproteins by one or more of 
the methods reviewed in this section. The analytical methods can be broadly divided into (1) 
biochemical methods, involving colorimetric or fluorescence reagents and labeling with or without 
additional separation by liquid chromatography; (2) antibody-based methods, including enzyme-
linked immunosorbent assay (ELISA) and immunostaining; and (3) mass spectrometric approaches, 
which usually require the combination of liquid chromatography with tandem mass spectrometry.  
Each of these approaches have advantages and disadvantages in terms of the complexity of the 
methodology and the quality or depth of information generated, two aspects that are usually 
directly related (Figure 3). Much early work used simple biochemical assays until the generation of 
antibodies specific for lipoxidation products allowed the application of immunoassays. Mass 
spectrometry techniques require complex and expensive instruments as well as extensive data 
handling, and consequently are less widely accessible, although very valuable as they yield site-
specific information that cannot be obtained by the other approaches. Ultimately, all the techniques 
provide complementary information, and are most powerful if used in combination. 
3.1. Biochemical methods with chromophore or fluorophore labeling  
In this section, techniques involving the use of reagents that generate a chromophore or 
fluorescent signal on reaction with the lipoxidized protein or lipoxidation agent are considered. 
However, it is important to bear in mind that not all methods are specific for lipoxidation: in fact, the 
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most used reagents are ones that react with aldehydes, which could also be formed by direct 
oxidation of amino acid residues.  Moreover, some of the methods used were indirect, for example, 
deducing the amount of modification by changes in amount of free rLPP or unmodified residues. 
For example, in one of the earliest studies of lipoprotein lipoxidation [23], involving the 
direct reaction of HNE with LDL, the formation of HNE-LDL adducts was determined indirectly by 
comparison of the amount of unreacted HNE in the supernatant of treated and untreated 
lipoproteins, which was quantified by high-performance liquid chromatography on an octadecyl 
silica (ODS) column with detection at 220 nm; the HNE incorporation was found to increase with 
increased aldehyde concentration, with 78% bound to the protein moiety, 21% to the lipids, and 1% 
as free aldehyde within the lipid fraction. To investigate more specifically the residues modified, the 
apolipoprotein B-100 (ApoB-100) was delipidated, reacted with dinitrofluorobenzene to 
dinitrophenylate and stabilize free hydroxyl and amine groups before total hydrolysis and 
quantitation using a standard amino acid analyser. This approach was adopted as it was noted that 
the adducts were not stable during the acid hydrolysis. Comparison of the levels of 
dinitrophenylated amino acids (i.e. those not modified by HNE) suggested that HNE attacked mostly 
lysine and tyrosine, and to a lesser extent, cysteine, serine and histidine [23]. The observation that 
tyrosine and serine could be modified is interesting as these residues are not widely considered as 
targets of hydroxyalkenals, but could simply have been an artefact of the experimental design with 
dinitrofluorobenzene. An alternative reagent that is more specific for detection of free amine 
groups, i.e. lysines, arginines and the N-terminal of proteins, is 2,4,6-trinitrobenzene sulfonic acid 
(TNBS).  This has been used in several studies to monitor indirectly protein modification by lipid 
peroxidation products [30–36]. 
Amino acid analysis was also used by Uchida et al. to investigate the sites of HNE 
modification in Cu2+-treated LDL, but in this case the adducts were stabilized by treatment with 
sodium borohydride (NaBH4) to prevent the issues noted by Jürgens et al. (1986) [23], and the amino 
acids were labeled with o-phthaldehyde for fluorescence detection during HPLC [37]. This enabled 
the quantification of approximately 40 lysines and 50 histidines (mol/mol LDL) modified in HNE-
treated LDL, of which 49% and 80% respectively were identified as Michael adducts, with the 
remainder as Schiff’s base adducts. However, this study also relied on complementary findings from 
the use of specific antibodies, as described in the next section. 
A commonly used reagent for detecting the presence of protein carbonyls is 2,4-
dinitrophenylhydrazine (DNPH) [38–40]. It reacts readily with protein-bound aldehydes or ketones to 
form a hydrazone derivative with a characteristic absorbance at 365 nm, and despite its mutagenic 
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properties and explosive nature (mostly now only available as a 0.2 M solution), continues to be 
widely used in studies of protein oxidation. However, its application to oxidation of lipoproteins has 
been limited. The formation of protein carbonyls in HOCl-treated LDL was investigated by Yang et al. 
using DNPH labeling followed by delipidation and tryptic cleavage of the ApoB-100; modified 
peptides were identified on HPLC by the absorbance at 365 nm, isolated and sequenced using a gas 
phase automated sequencer [41]. The modified peptides contained cysteine, lysine, tryptophan and 
methionine residues; it was not clear from this study whether the modifications were due to direct 
oxidation of the residues by HOCl, or formation of rLPPs that reacted with the cysteine to give 
Michael adducts. In the use of DNPH as a labeling reagent for lipoxidation, it is also important to 
bear in mind that Schiff’s base adducts of hydroxyalkenals do not contain a free aldehyde to react 
with DNPH; instead, DNPH may react via Michael addition with them to generate 2,4-dinitrophenyl 
pyrazolines, which have a slightly shifted absorbance maximum compared to hydrazones. Moreover, 
when using DNPH to study lipoxidation in Cu-oxidized LDL it has been observed from the judicious 
use of controls in the absence of DNPH that the tryptophan oxidation products N-formyl kynurenine 
and kynurenine have significant absorbance at 365 nm, which can confound the detection of protein 
carbonyls, so careful profiling of the labeled peptides is necessary [42].  
Alternatively, the thiobarbituric acid reactive substances (TBArS) assay can be used to 
measure malondialdehyde (MDA) equivalents present in the sample, including MDA adducts on the 
protein, which are reversible under the conditions used for the assay. The reaction between 
thiobarbituric acid and MDA yields a pink chromophore with an absorbance maximum at 535 nm. In 
its simplest form, the TBArS assay has been widely criticized as a measure of lipid peroxidation in 
complex samples (reviewed by Halliwell & Chirico [43] and Spickett et al. [44]), but under stringent 
conditions, especially when combined with HPLC separation, it can be used to monitor LDL oxidation 
[34,36,37,45–48].   Hoff et al. used the TBArS assay combined with TBNS analysis of free amines to 
show that, similarly to the HNE-LDL modification reported previously [23], MDA modification of 
ApoB-100 increased with increased MDA treatment concentration, and appeared to be correlated 
with the decrease of available amines [49]. This is in accordance with previous reports of decreases 
in lysine availability upon treatment of LDL with MDA [32].  
While these colorimetric assays may now seem somewhat simplistic, they were 
nevertheless crucial in building evidence on the occurrence of covalent modifications of LDL by short 
chain non-esterified aldehydes.  In contrast, a rather different approach was adopted by Karakatsani 
et al. to investigate lipoxidation by phospholipid-esterified rLPPs [50]. They used both a phosphorus 
assay and 31P nuclear magnetic resonance (NMR) to measure the phosphorus in the delipidated 
ApoB-100 fraction of Cu-oxidized LDL. They identified an NMR peak that appeared to correspond to 
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the phospholipids bound to the protein by hydrophobic bonds, which disappeared upon treatment 
with phospholipase A2 (PLA2), showing that even in the delipidated protein there is still a fraction of 
bound phospholipid. Furthermore, they identified a second peak, not hydrolyzed by PLA2, which 
appeared to correspond to the oxidized phosphatidylcholine fraction that formed covalent adducts 
with the proteins. This finding was not corroborated until several years later by complementary 
techniques involving antibodies and LC-MSMS analysis, described in later sections. 
3.2. Antibody-based detection of apolipoprotein lipoxidation  
Antibodies are an extremely useful tool for biomolecular and biochemical techniques used 
throughout the biosciences and biomedical sector. From detection methods to therapeutics, they 
are utilized in variety of fields owing to their ease of use and, at least for polyclonal antibodies, 
relatively quick and inexpensive production. These characteristics also make them very attractive for 
commercial development. The generation of antibodies against specific aldehydes, usually in the 
form of protein adducts, has allowed the identification of lipoxidized lipoproteins by an array of 
immunotechniques, and without doubt has underpinned many key advances in this field [10,16]. 
Several groups have worked on the development of such antibodies, characterized them, and used 
them to investigate possible biological effects of oxidized lipoproteins, and their role in certain 
pathological conditions, mainly atherosclerosis.  
3.2.1 Development and application of anti-MDA Antibodies 
The first application of antibodies against rLPP-modified lipoproteins were using either 
previously existing antibodies against MDA-lysine adducts [51], or polyclonal antibodies raised 
against MDA-treated LDL [52]. The MDAlys monoclonal IgG2A was selected for binding  ability to 
MDA-modified LDL but not to native human LDL, and was able to detect MDA-modified proteins by 
immunocytochemistry and their colocalization with ApoB-100 in atheromas from rat [51]. In 
contrast, an ELISA was developed using the polyclonal anti-MDA-LDL that appeared to bind to MDA-
ApoB adducts in MDA-treated LDL, while not recognizing native LDL, acetyl-LDL or MDA-HDL, 
suggesting that the antibody was both modification- and protein-specific [52]. Both studies were 
important for the establishment of this approach, which has subsequently been used extensively for 
lipoproteins. Anti-MDA monoclonal and polyclonal (e.g. MAL-2) antibodies produced using either 
rabbits or guinea pigs were later used to identify the presence of adducts of this aldehyde bound to 
ApoB100 in copper-oxidized LDL, using techniques such as western blotting using the monoclonal 
antibodies MDA2 and OLF4-3C10 [32,53] and a solid-phase fluorescence assay [54].  
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3.2.2 Development and application of anti-HNE Antibodies 
In view of the identification of HNE as a major cytotoxic lipid peroxidation product, it is not 
surprising that much effort was invested in producing anti-HNE antibodies, with both polyclonal sera 
and monoclonal antibodies being produced against HNE-treated LDL, or HNE bound to other 
proteins or peptides.  In parallel with their work on MDA-LDL antibodies, Palinski et al. produced an 
antiserum (HNE-6) and a monoclonal antibody (NA59) against HNE-LDL, which they reported were 
specific for HNE-lysine adducts [53]. The monoclonal and polyclonal antibodies were used to identify 
the presence of HNE-LDL adducts in copper-oxidized LDL and atherosclerotic lesions, and did not 
recognize unmodified LDL [32].  Polyvalent antisera to HNE-modified LDL were also raised in rabbits 
by Esterbauer’s group [47,55]. It was found that the antiserum recognized LDL treated with either 
HNE or CuSO4, but not MDA, hexanal, 2,4-heptadienal or 4-hydroxyhexenal, while there was a small 
cross-reactivity with 4-hydroxyoctenal. This demonstrated the specificity of the polyvalent serum to 
the nine carbon hydroxyalkenal, but interestingly it was also shown that copper-oxidized Lp(a) and 
VLDL both cross-reacted with the antiserum, indicating that the specificity was due to the adduct 
and not the lipoprotein.  The work also provided confirmation that oxidation of these lipoproteins 
resulted in HNE formation and lipoxidation [47]. Later the group prepared a further polyclonal 
antiserum to HNE-LDL and reported weaker binding to oxidized and HNE-treated HDL3 or bovine 
serum albumin, but noted some cross-reactivity to hexanal- or 2,4-heptadienal-modified LDL [55], 
illustrating the variability inherent in polyclonal preparations.  They hypothesized that MDA might 
react differently to HNE and other aldehydes due to its chemical structure, being a bivalent 
aldehyde. Based on competition studies using  HNE-treated poly(L-amino acids) lysine, tyrosine, 
arginine and histidine, it was concluded that these residues were possible sites of modification; no 
binding to the corresponding untreated poly(L-amino acids) was observed [55].  Other researchers 
also prepared and tested antisera against HNE-LDL and MDA-LDL from rabbit by fluorescence 
sandwich immunoassays or solid-phase radioassays, and used them to investigate the binding of 
lipoxidized LDL to extracellular matrix components [54]. 
Other studies also investigated the sites of HNE-lipoxidation in other modified proteins and 
the epitopes responsible for antibody recognition. The group of Uchida raised monoclonal 
antibodies against HNE-keyhole limpet hemocyanin (KLH) and demonstrated using ELISAs that they 
were able to recognize HNE adducts in HNE-LDL, copper-LDL and endothelial cell-treated LDL in a 
concentration dependent manner [37].  Further experiments showed that the antibodies only 
recognized the HNE moiety of the adduct, as their binding to the modified LDL was blocked when 
incubated in the presence of HNE-modified amino-acids (HNE-N-acetyl-lysine, HNE-N-acetyl-
histidine) or HNE-glutathione. This agreed with the results of Chen et al. [55] and suggested that for 
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these antibodies the binding was not protein-specific, or indeed particularly residue-specific [37]. 
However, shortly afterwards the development of monoclonal antibodies with specificity against 
HNE-histidine adducts and very limited recognition of HNE-lysine and -cysteine adducts was 
reported [56]. In this study, the antibodies were raised against HNE-modified bovine serum albumin, 
but were able to recognize HNE-protein adducts in peroxidized liver microsomes as well as in 
oxidized LDL. There was no detectable cross reaction with adducts of malonaldehyde, nonanal or 4-
hydroxyhexenal, although eight and ten carbon hydroxyalkenals showed some reaction. While not 
specific for lipoxidized lipoproteins, it can also be considered an advantage of these antibodies that 
they can be used for the identification of any HNE-lipoxidized proteins. 
3.2.3 Development and application of antibodies against other alkenals and hydroxyalkenals 
  While the early focus was very much on developing antibodies against MDA and HNE, 
subsequently the interest expanded to include other aldehydes known to be formed upon 
phospholipid peroxidation. The carcinogenic, three carbon alkenal acrolein can be formed from lipid 
peroxidation but also occurs in tobacco smoke and as an environmental pollutant, and is therefore 
of considerable interest. A monoclonal antibody (mAb5F6) that reacts selectively with acrolein-lysine 
adducts was raised in mice using KLH treated with acrolein as an immunogen [57], and then utilized 
to demonstrate lipoxidation of the N-terminal region of Apolipoprotein E-III (ApoE-III) (normally 
present in HDL, VLDL and IDL) by this aldehyde with corresponding impairment of ApoEIII-heparin 
binding [58].  4-hydroxyhexanal (HHE) is the 6-carbon analogue of HNE and is also a significant 
product of lipid peroxidation; antibodies raised against a protein modified with this aldehyde were 
used to identify the presence of these adducts in copper oxidized LDL [46]. Specifically, the antibody 
clone used (HHE53) had been shown to be inhibited in the presence of HHE-N-acetyl-histidine, but 
not other amino acids, suggesting that HHE bound to the histidine residues of ApoB-100 in copper 
oxLDL [46]. The same approach was used to raise an antibody against 4-hydroperoxynonenal (HPNE) 
adducts (clone PM9), and it was found that 4-hydroperoxy group leads to formation of structurally 
unusual lysine adducts that were specifically recognized by the antibody aldehydes [59]. It was used 
to demonstrate the occurrence of HPNE lipoxidation in copper-oxidized LDL, which was verified by 
western blot analysis, as well as in lesions in samples of the aortic wall of patients with generalized 
arteriosclerosis, demonstrated by immunohistochemistry [59]. More recently, monoclonal 
antibodies were developed against protein adducts of the twelve carbon compound 4-hydroxy-
2E,6Z-dodecadienal (HDDE); these were used to identify adducts in human aortic section, but as yet 
have not been demonstrated to bind to lipoproteins or used in specific studies of their oxidation 
[60].  
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3.2.4 Development and application of antibodies against oxidized lipoproteins 
Besides the development of antibodies against specific aldehydes described above, several 
groups also developed antibodies against copper-oxidized LDL [32,53,54,61]. Further 
characterization of two antibodies developed (OB/04 and OB/09) uncovered their reaction not only 
with copper-oxidized LDL, but also with azo-initiator oxidized LDL and copper-oxidized VLDL, while 
not reacting with the oxidized HDL3 or any of the native forms of the lipoproteins [61]. This 
suggested that the epitopes of these antibodies were generated against modified portions of 
apolipoproteins present in LDL and VLDL, but not in HDL3.  
An alternative approach that has proved very valuable is the isolation of autoantibodies 
produced during a diseased state; for example, autoantibodies present in mice with aortic 
atherosclerosis caused by a high fat diet, designated E0 antibodies, were found to bind a variety of 
modified forms of LDL, including LDL modified by copper, acrolein, MDA and HNE [62–64]. One of 
the autoantibodies, E06, was subsequently extensively studied, and was found to bind to the 
phosphocholine head group of oxidized phosphatidylcholines [31], thus binding to both oxidized 
phospholipids and oxidized phospholipid-protein adducts. As it is not ApoB-specific, it is also able to 
recognize copper-oxidized HDL, demonstrating the existence of phospholipid-esterified aldehyde 
adducts in lipoproteins [62]. Antibody E06 [64] is now commercially available and has been used for 
detection of oxLDL in clinical samples, as discussed in Section 5. It is worth noting that in early 
publications this antibody was referred to as EO6 (Horkko et al., 1999), but now the name E06 is 
more commonly used, including by the commercial supplier Avanti Polar Lipids. 
3.2.5 Considerations in the utilization of antibodies against lipoxidized proteins 
It is important to bear in mind that there has been considerable variability in the methods of 
production of the antibodies discussed above, although much of the testing was carried out against 
human lipoproteins or tissue samples. As a consequence, there are substantial difference in 
specificity and sensitivity between the antibodies that must be borne in mind when interpreting the 
results, and which explain the different cross-reactivities reported. 
Nevertheless, antibodies show great potential as a sensitive technique for the identification 
of lipoxidation in lipoproteins and have facilitated the development of methods for detecting and 
identifying lipoxidation, both in plasma and tissue samples. This has supported our understanding of 
the biological effects of these modifications [58], which is explored further in Section 4, as well as 
helping to evaluate the potential of therapeutic techniques [65], discussed in Section 5. A key 
advantage of immunoassays is their simplicity and accessibility, with most biological laboratories 
well set-up for ELISAs, western blotting and immunocyto/histochemistry. The potential for 
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quantitative analysis is also important, although dependent on well-characterized standards. On the 
other hand, these methods provide limited information on the site of modifications within the 
lipoproteins. Where the antibody is specific for a type of adduct, the residues modified can be 
inferred, and has for example been used to calculate that oxidized LDL contains 3 nmol HNE-histidine 
per mg protein [56]. However, identification of the precise residues that are modified requires the 
application of advanced protein analysis by LC-MSMS, as explained in the next section. 
3.3. Advances in mass spectrometry approaches for analysis of lipoxidation 
3.3.1 LC-ESI-MS(MS) analysis of amino acid lipoxidation (non-site-specific) 
With the development of LC-ESI-MS, later followed by tandem mass spectrometry and 
peptide sequencing, their application for the identification of modified lipoproteins was inevitable. 
One of the first reported uses of mass spectrometry for the direct measurement of aldehyde adducts 
identified MDA and HNE adducts to the lysine residues of copper oxidized LDL, by protein hydrolysis 
and GC-MS [34]. The study reports not only the identification of adducts of MDA (3-(Nε-
lysino)propan-1-ol) and HNE (3-(Nε-lysino)-4-hydroxynonan-1-ol), but also a lysine-MDA-lysine 
iminopropene crosslink (1,3-di(Nε-lysino)propane). While lysine-MDA adducts were found even in 
LDL from healthy subjects, their increase and the formation of lysine-HNE adducts during copper 
oxidation of LDL was found to account for the modification of less than 1% of the lysine amino acids 
present in LDL [34]. This emphasizes the challenges of studying such modifications [66]. 
GC-MS has been used in the identification of several fatty acids adducted to copper 
oxidized LDL [45]. Acid hydrolysis was performed on delipidated apolipoproteins, and the fatty acids 
released were analysed by selected ion monitoring-GS-MS (SIM-GC-MC), together with a phosphorus 
assay. The carboxylic acids found to be increased in oxidized LDL included pentanedioic (glutaric) 
acid (PDA), nonanedioic (azelaic) acid (NDA), hexanoate, palmitate, stearate and oleate; the latter 
three showed a 10 to 20-fold increase. These results were interpreted as the formation of adducts 
between proteins and phospholipids, which had also been suggested previously by antibody studies 
[45], although it is known that total delipidation of lipoproteins is very difficult and non-covalently 
bound lipids often remain [50,67]. LC-MS of hydrolyzed samples was also used to demonstrate that 
pyridoxamine could the inhibit the formation of several advanced lipoxidation end products, 
specifically N-(carboxymethyl)lysine (CML), N-(carboxyethyl)lysine (CEL), malondialdehyde-lysine, 
and 4-hydroxynonenal-lysine, in the copper-catalysed oxidation of LDL [68].  
Uchida’s group in Japan have worked intensively in this area using the approach of total 
protein digestion by 6N HCl followed by LC-MSMS analysis of modified amino acids.  Lipoxidation 
adducts of trans-2-nonenal [69], 4-oxo-2(E)-nonenal [70], and acrolein [71] were detected in LDL 
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oxidized in vitro. More recently, they have developed a methodology to investigate the lipid 
peroxidation “adductome” of LDL [72], based on the fact that different lipoxidation adducts of, for 
example, lysine have different retention times in the LC run and different mass-to-charge ratios. In 
LC-MSMS, a precursor ion scan for diagnostic fragments of the amino acid moiety was used to 
identify the precursors, i.e. the modified amino acids. The effectiveness of the method was 
demonstrated with Cu(II)-oxidized LDL and allowed the quantification of known adducts such as 
those of 4-hydroxynonenal and acrolein, as well as identifying new adducts such as 9-oxononanoic 
acid-lysine, which was detected in the reduced form as Nε-(8-carboxyoctanyl)-lysine (COL), and 
thought to originate from either 9-oxo-7-nonenoic or 9-oxononanoic acid.  The methodology was 
further applied to identify increases in COL in LDL from hyperlipidemic rats, as well as from 
hyperlipidemic subjects [72]. 
While clearly providing very useful information on the types and amounts of modifications 
present in the lipoproteins, analysis of hydrolysed residues cannot locate the individual residues 
modified within the apoprotein, information that is important for understanding the various 
biological effects of lipoxidation. Localization of modified residues within a protein requires the 
sequencing of peptides in a proteomics approach using tandem MS analysis, as described below. 
3.3.2 LC-MSMS proteomic approach for localization of lipoxidized residues within peptides (site-
specific) 
More recently, tandem mass spectrometric methods have become more common, such as 
MALDI-MS/MS and LC-ESI-MS/MS. The basic principles of the methods applied to the analysis of 
oxidized and lipoxidized proteins have been explained in previous reviews [73] and will not be 
covered here. Most work has been carried out by the “bottom-up” approach, which involves 
enzymatic digestion of proteins to peptides, which can be separated by LC, and then fragmented 
within the mass spectrometer to enable sequencing. This approach is not trivial for the localization 
of any oxidative modification [73], and analysis of lipoxidation is even more challenging [66]. For 
lipoxidation adducts, which are not particularly stable (Schiff’s base adducts are readily reversible 
and even Michael adducts can degrade), it is important to “fix” the adducts by a reduction step 
before commencing the proteolysis steps. A smaller number of studies have used a “top-down” 
approach, which analyses the intact protein complete with modifications, and then partially 
fragments it to provide further information. Some of these techniques have also been discussed by 
Colzani et al. in a review on mass spectrometric approaches for the analysis of protein adducts with 
reactive carbonyl species, which provides a detailed consideration of the approaches for the analysis 
of more complex biological samples, including lipoproteins, and the use of derivatization with DNPH 
for the MS identification of acrolein, HNE and MDA adducts with proteins [74]. The derivatization 
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approaches can also be carried out with alternative labeling agents such as the hydroxylamine-
functionalized biotin-containing probe, aldehyde reactive probe (ARP), and have been tested by 
several groups in general redox proteomic studies [16,66,75], but have not been applied to studies 
of lipoproteins. 
3.3.3 Application of proteomic approaches to identify sites of LDL lipoxidation by small rLPPs 
One of the earliest studies to attempt to identify specific sites of lipoxidation in ApoB-100 
used a targeted bottom up approach to look for HNE adducts of histidine in copper-oxidized LDL 
[76]. Following treatment, the LDL was extracted and the protein digested with trypsin in solution, 
before being studied using both ESI-MS to identify the mass of the peptides and precursor ion 
scanning (PIS) of a fragment ion at m/z 268, which corresponds to the reduced HNE-modified 
histidine immonium ion and allows peptides containing this modification to be found [77]. The group 
attributed most of the parent ion peaks resulting from the PIS to theoretical HNE-modified ApoB-100 
peptides, tentatively localizing the modifications to six histidine containing peptides [76].  Later they 
used this approach to study the effect of HDL on LDL oxidation.  By carrying out a quantitative 
analysis of specific histidines, they were able to demonstrate that the presence of human HDL, 
which contains the anti-oxidative enzyme paraoxonase, abrogated the lipoxidation of LDL histidines, 
whereas avian HDL, which lacks paraoxonase, did not [77].  Modifications in ApoB-100  induced by 
copper oxidation of LDL were also investigated using an untargeted LC-MSMS approach by Obama et 
al., and a variety of amino acid oxidations were observed (mono-oxidations of histidine and 
tryptophan and kynurenine), as well as HNE-histidine and N-(3-methylpyridinium)-lysine 
lipoxidations resulting from acrolein modification [78]. A key novelty in this work was the testing of 
both in-gel and on-membrane (polyvinylidene difluoride; PVDF) trypsin digestion, which enabled 
much smaller amounts of lipoprotein to be used [78], compared to the previous work by Bolgar et al. 
where milligram amounts were used [76]. 
3.3.4 Application of proteomic approaches to identification of sites of HDL modification by small 
rLPPs 
LDL is particularly challenging lipoprotein to work with for MS-based proteomic analysis, as 
ApoB-100 is a very large protein consisting of 4,536 amino acid residues with a molecular weight of 
over 500 kDa.  In contrast, the proteins from HDL present a more amenable target: approximate 
molecular weight for ApoA-I is 28 kDa, ApoA-II is 18kDa, and ApoC forms are 8-9 kDa.  Consequently, 
in parallel other groups have studied the oxidative modifications of HDL, with reasonable success. 
Heinecke’s group carried out several investigations of apolipoprotein A-I (ApoA-I) using untargeted 
LC-MSMS methods, and succeeded in obtaining 80% sequence coverage, enabling a fairly thorough 
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assessment of the modifications. While their focus was mainly on the chlorination and nitration of 
tyrosine residues by myeloperoxidase [79], they also investigated the reaction of acrolein with ApoA-
I [80].  Using the endoproteinase GluC to digest the protein, they obtained 90% sequence coverage 
and were able to identify eight specific lysine residues modified to Nε-(3-methylpyridinium)lysine 
(MP-lysine); Nε-(3-formyl-3,4-dehydropiperidino)lysine (FDP-lysine) did not appear to be formed and 
no cysteine modifications were detected because ApoA-I lacks this amino acid. Interestingly, using 
the monoclonal antibody mAb5F6mention in Section 3.2.3, they were able to show that ApoA-I 
colocalized with acrolein-lysine adducts in human atherosclerotic lesions. The modification of both 
ApoA-I and ApoA-II by acrolein has been investigated by Chadwick et al. to determine its role in HDL 
cross-linking and impairment of the reverse cholesterol transport pathway in peripheral tissues [81]. 
This demonstrated the occurrence of mass shifts corresponding to the addition of acrolein molecules 
by both Michael addition and Schiff base on intact ApoA-I and ApoA-II proteins, and related it to the 
formation of crosslinks seen in western blots, but as only intact protein analysis was carried out, the 
sites of adduct formation were not identified. 
Lipoxidation of the HDL protein component ApoC-II has also been studied, using a more 
unusual rLLP derived from the ozonolysis of cholesterol, 3β-hydroxy-5-oxo-5,6-secocholestan-6-al (3-
HOSCA) [82]. There is evidence that co-localization of ApoC-II and serum amyloid P in atherosclerotic 
plaques can lead to the formation of fibrils, and previous data from studies in vitro demonstrated 
that treatment of ApoC-II with 3-HOSCA accelerates fibril formation. To investigate the formation of 
covalent adducts, ApoC-II was incubated with 3-HOSCA, digested with GluC, separated by HPLC and 
then analysed by MALDI-TOF-MS to identify modified peptides; however, as the peptides were large 
(~40 residues), the likely site of modification within them could only be inferred. Nevertheless, the 
study demonstrated that ApoC-II could be randomly modified at six different lysine residues, 
typically resulting in one 3-HOSCA attached per ApoC-II molecule, and it was concluded that the 
presence of this adduct in HDL leads to the formation of fibrils by both covalent Schiff base 
formation, and other non-covalent mechanisms [82]. 
Acrolein adducts have also been identified and located in rat ApoE, which is a 294 amino 
acid protein with a molecular weight of 34 kDa, and about 74% sequence homology with human 
ApoEIII. The protein was digested with endopeptidases AspN and GluC to improve sequence 
coverage, before analysis by matrix-assisted laser desorption/ionization time-of-flight/time-of-flight 
mass spectrometry (MALDI TOF/TOF MS). Using this untargeted approach, the researchers were able 
to find acrolein modifications yielding an aldimine adduct at K149 and K155; a propanal adduct at 
K135 and K138; MP-lysine at K64, K67, and K254, and an FDP-lysine derivative at position K68. These 
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lipoxidations were concluded to contribute to impairment of binding to the LDL receptor and 
heparin, and may also be responsible for protein unfolding [83]. 
3.3.5 Application of proteomic approaches to localization of adducts formed by phospholipid-
esterified rLPPs 
The research described above has focused on adducts formed by small, non-esterified 
alkenals, but it is well-established that phospholipid-esterified alkanals or alkenals are also major 
products of lipid oxidation, and antibody-based studies described in Section 3.2 suggested that they 
can also form adducts with proteins. To confirm their formation and identify the sites of 
modification, studies of LDL oxidation were carried out by the group of Spickett [67]. LDL was 
treated with the esterified nine-carbon alkanal 1-palmitoyl-2-(9-oxo-nonanoyl)-sn-glycero-3-
phosphocholine (PONPC), delipidated and in gel-trypsin digestion carried out, followed by LC-
MS/MS; approximately 70% sequence coverage of ApoB-100 was obtained, which was good 
considering the size of the protein. In this work a novel targeted mass spectrometry approach was 
developed, involving the use of narrow-window extracted ion chromatograms (XICs) to pinpoint the 
presence of characteristic fragments of certain modifications.  These included the m/z 184 ion, an 
intense fragment commonly formed during fragmentation of phosphatidylcholines, corresponding to 
the head group. They were able to identify two different peptides modified with PONPC and one 
modified with the analogous 5-carbon alkanal, 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-
phosphorylcholine (POVPC). This was the first published report to identify directly and localize 
lipoxidation adducts of chain-shortened phospholipids.  
There is also substantial evidence that adducts of oxidized PC are present on Lp(a), a 
lipoprotein formed by covalent linking of ApoA to ApoB-100 [84].  The adducts are formed as Schiff 
bases to two lysine residues within Kringle IV or Kringle V domains of the ApoA.  Recombinant 
Apo(a)s were used to investigate the lysine binding site (LBS) responsible for adduct formation, using 
both E06 antibody binding and analysis of tryptic peptides by LC-MSMS. Precursor ion scanning for 
m/z 184 was again employed to show the presence of a number of prominent peptide peaks 
containing PC, and analysis of the lipid phase of the lipoprotein demonstrated the presence of the 
short chain aldehyde POVPC, which is E06-detectable [85]. 
Shortly afterwards, an alternative method for identifying oxidized phospholipid adducts 
was developed and applied to using the modification of ApoA in HDL [86]. A key advantage in this 
study was the use of an enrichment process consisting of two separations steps. The first one 
separated the phospholipid-modified peptide, which is highly hydrophobic, from less hydrophobic 
molecules using a C18 column. Subsequently aminolysis was carried out; this is a specific reaction 
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that breaks the bond between the phosphoglycerol backbone and the fatty acyl chain at the sn-2 
position, thus separating the PC head group and intact long hydrophobic chain from the modified 
peptide, making the latter more hydrophilic and allowing it to be eluted from the column. Using this 
method, the group was able to identify a plethora of peptides of ApoA-I, II and III from copper-
oxidized HDL [86] and myeloperoxidase-oxidized HDL [87], demonstrating the modification with 
several different oxidized phospholipids. 
It can be seen that mass spectrometry analysis of lipoxidation is a challenging but evolving 
field: the rate at which papers are published in this area is increasing, the data obtained on the 
modifications is getting more detailed, and the development of the technology is allowing the 
analysis of more complex samples. The different approaches: amino acid analysis versus peptide 
sequencing are quite complementary in the information produced; the former is very good for 
quantitative studies, whereas the latter is able to identify specific residues that are modified, and 
therefore enables the mechanisms of function or dysfunction to be elucidated. From the peptide 
sequencing methods, a substantial body of evidence on the sites of modification of several 
apolipoproteins has now been obtained and is illustrated in Figure 4. A key challenge is now to 
understand the functional effects of these modifications. 
 
4. Biological effects of lipoxidized lipoproteins  
Since the discovery of the role of oxidized LDL in pathologies like atherosclerosis, some 
effort has been put into understanding the biological effects this lipoprotein can have, especially in 
pathology. Many reviews have been published on the subject, from its role in atherosclerosis [13,88–
90], apoptosis [91] and inflammation [92], its growth and proliferation promoting effects [93], its 
involvement on endothelial dysfunction and ageing [94], among others. Although for oxidized HDL 
not as much research has been done, some of its effects have also been uncovered, and it is clear 
that the beneficial effects of this lipoprotein can be lost following covalent modification.  Oxidation 
of this lipoprotein induces the loss of its protective effect against oxidized LDL [95], and that in turn 
induces further oxidative stress and cytotoxicity (although to a lower extent than oxLDL) [96]. The 
effect of oxHDL has also been shown on the dysfunction of endothelial progenitor cells (EPCs) and 
human renal proximal tube epithelial cells (HK-2), through activation of CD-36 receptors and 
mitogen-activated protein kinase (MAPK) pathways [97,98], as well as on the induction of 
adipogenesis in females with high body mass index (BMI) [99].  
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While a lot has been done to uncover the biological effects of oxidized lipoproteins, 
relatively little of this work is on the effect of lipoxidized lipoproteins specifically. Figure 5 
summarizes the main biological effects that have been reported to date. Much of the work has 
focused on MDA- and HNE-modified LDL.  As early as 1980, MDA-treated LDL was used as a model 
system and was shown to be taken up by macrophages, but the mechanisms were poorly 
understood; it was hypothesized that the malondialdehyde modified LDL particles shifted their 
binding from the native-LDL receptor to a scavenger receptor, thus promoting their uptake [100]. 
While characterizing the E06 antibody, known to bind to oxidized phospholipids and oxLDL, it was 
shown that this antibody blocked the uptake of oxLDL by the macrophages, and that the decrease of 
the phospholipid moiety bound to ApoB-100, decreased the affinity of oxLDL to macrophages, and 
the reactivity with the antibody [36]. Further studies found that several scavenger receptors bind 
oxLDL, namely SRA-1, SRA-2, SRA-3, MARCO, CD36, SR-B1, CD68, and LOX-1 [101,102]. Two in 
particular, CD36 and SR-B1, were shown to interact with both the protein and the lipid present in 
oxLDL separately, and their binding was also inhibited by the E06 antibody and the oxidized 
phospholipid POVPC, suggesting it was the oxidized moiety present in the lipid fraction or bound to 
the protein fraction that mediated the high affinity binding of oxLDL to the receptor CD36 [103,104].  
Other studies showed that in oxidized LDL and MDA-treated LDL with similar degrees of 
modification,  oxLDL showed higher binding to macrophages and degradation rate when compared 
to MDA-LDL [105]. It has been reported that MDA-treated LDL induced THP-1 cell growth, which 
could be suppressed by polycyclic aromatic hydrocarbons (PAHs) in an arylhydrocarbon receptor 
(AhR)-dependent manner; it was suggested that this resulted from the link between AhR and p21 
leading to cell cycle arrest [106].  An association between the levels of circulating MDA-LDL and 
vascular inflammation has been reported, using 18F-FDG PET/CT imaging [107], and it was suggested 
that part of this inflammation might be due to activation of the complement system, by the binding 
of MDA and malondialdehyde acetaldehyde (MAA) adducts in treated LDL to the complement 
anaphylatoxin C3a [108]. HNE-modified LDL is also thought to have altered functionality; it has been 
reported that HNE-containing oxLDL can induce cell proliferation at low levels in smooth muscle 
cells, while at higher levels it caused apoptosis in various cell types [109,110].  This oxLDL-induced 
apoptosis might be linked to the derivatization of proteins such as tyrosine kinase receptors by HNE 
[109,110] and possibly other oxidized lipids, and to the inhibition of the ubiquitin-proteasome 
pathway [111]. 
Oxidation of LDL has also been shown to stimulate the production of antibodies against 
oxidized PC species. Structural and functional similarities between the E06 antibody and T15, an 
anti-oxPC secreted by B-1 cells and involved in the immune response provoked by bacterial infection 
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with S. pneumoniae, have been uncovered [112]. They suggested that oxidation of PC species, 
and/or possibly their addition to protein residues, alters their conformation, exposing the PC 
headgroup and making it accessible to the antigen binding site of E06/T15 antibodies. The 
production of such antibodies has an important biological effect, since they have the ability to inhibit 
the uptake of oxLDL by macrophages, as mentioned previously [64]. At this time, it was still unclear 
whether they were autoantibodies, i.e. antibodies produced by the body against part of “self”, or if 
the modified proteins and lipids were being recognized as external factors [112]. Similarly, 
antibodies found in human plasma that bound to oxidized and MDA modified LDL have been tested, 
and results show that one in particular, IK17, binds to MDA-LDL, MDA-HDL and Cu-oxidized LDL, 
whilst not binding to LDL treated with HNE or other proteins modified with MDA, suggesting a 
specific affinity to protein-bound MDA [113]. This antibody was also able to block the uptake of 
oxLDL by macrophages, which is important as it could potentially be used in therapeutics. In 
contrast, another study reported that when human LDL was injected into immune-competent and 
immune-deficient mice (lacking B and T cells), extensively oxidized LDL was cleared faster than 
native LDL but with similar clearance rates in the two mouse types, suggesting that the clearance of 
oxLDL is not simply mediated by antibody production [114]. However, there is now extensive 
evidence that covalent adducts such as ALEs or AGEs constitute “damage associated molecular 
patterns” (DAMPs) and are recognized by the immune system. They are often referred to as 
oxidation-specific epitopes, or OSEs; they occur on the surfaces of lipoproteins, apoptotic cells [115] 
or microvesicles [116], and can be recognized by a wide variety of cell surface pattern recognition 
receptors central in innate immunity, such as scavenger receptors and some Toll-like receptors 
(reviewed by [117,118]). The lipoprotein modifications most typically studied in this context are 
MDA, HNE and oxPCs, probably because these are most readily analysed, but it is highly likely that 
modifications by other rLPPs also contribute but have not yet been identified.  The autoantibodies 
(also called natural antibodies or Nabs) produced downstream of the immune activation, and 
reported in patients with a variety of inflammatory diseases, are often IgMs although IgGs also occur 
[118]. 
 Another lipoprotein that that has been quite well-studied owing to its proatherogenic 
effects is Lp(a), which is an ApoA covalently linked to ApoB-100 by a disulfide bond [119]. It appears 
to be quite well-established that Lp(a) can bind covalently to oxidized phosphatidylcholines via lysine 
residues in the Kringle V domain [120], and it has been found that Lp(a) is the preferred carrier of 
oxidized phospholipids (oxPLs) in plasma [121]. Lp(a) has been reported to have various pro-
inflammatory effects that appear to depend on the presence of the oxPL adduct. For example, 
Edelstein et al. reported that human apo(a) induced the production of interleukin 8 by cultured THP-
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1 macrophage-like cells [120]; subsequently this was confirmed in THP-1 and U937 cell lines and the 
use of siRNA indicated that both CD36 and TLR2 contributed to the effect. Inhibitors of MAPKs, Jun 
N-terminal kinase and ERK1/2 were found to abolish IL-8 gene expression, suggesting that these 
signaling pathways are involved in the response downstream of the receptors [84]. Overall, there is 
mounting evidence that a Schiff base adduct on lysine in the Kringle IV type 10 is responsible for the 
pro-inflammatory and pro-atherogenic properties of this lipoprotein. There has also been interest in 
anti-neoplastic effects of Lp(a), which may be caused by degradation products of the lipoprotein, 
although convincing evidence is only just emerging [119] and the importance oxPC adducts in this 
effect is not established. 
Some studies of HDL have reported altered biological activity following lipoxidation by 
acrolein. In particular, acrolein modification of ApoE was found to destabilize the protein, and 
caused a significant decrease in its ability to bind 1,2-dimyristoyl-sn-glycero-3-phosphocholine 
(DMPC) and support cholesterol efflux from cholesterol-loaded J774 mouse macrophages. The 
modified HDL also showed decreased binding to the LDL receptor in a co-immunoprecipitation assay 
and decreased binding affinity on a HiTrap heparin-sepharose column [83]. Similar findings were 
reported by Chadwick et al. [81], who showed that HDL cross-linked by acrolein was less able to act 
as an acceptor of free cholesterol from COS-7 cells, compared to native HDL. In fact, acrolein-HDL 
increased the neutral lipid uptake into macrophages. Thus it can be seen that acrolein modification 
caused substantial disruption of HDL structure, leading to a dysfunctional particle with impaired 
ability to support the reverse cholesterol transport pathway, with consequent atherogenic effects. 
 
5. Lipoxidized lipoproteins as markers of disease and their use in therapeutics discovery 
The altered biological effects described in the previous section are in the main pro-
inflammatory, and therefore can be expected to contribute to a variety of diseases with underlying 
inflammatory etiology.  It has long been accepted that LDL oxidation and ApoB-100 modification lead 
to impaired and altered biological functions that contribute to the progression and pathology of 
atherosclerosis [122], but lipoproteins can also be involved in the pathophysiology of other diseases. 
For example, dyslipidemia is associated with chronic kidney disease, diabetes mellitus and metabolic 
syndrome, and is characterized by lipoprotein abnormalities including an increase of triacylglyceride-
rich lipoproteins such as VLDL and chylomicrons, LDL particles that are smaller and more dense, and 
an overall decrease in HDL cholesterol [123,124].  HDL deficiency or dysfunction have also been 
implicated in neurodegenerative disorders: high levels of this lipoprotein appear to correlate with 
increased cognitive function and memory in the senior demographic [125], but in Alzheimer’s 
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disease a certain genotype of ApoE, allele APOE-ԑ4, has been shown to predict an accelerated 
decline of cognitive function in carriers [125], although there is no evidence that it is related to 
increased susceptibility to lipoxidation.  
The development of techniques to localize and identify lipoxidation, reviewed in Section 3, 
has allowed its analysis in clinical samples. A strong focus, going back more than twenty years, has 
been on lipid-protein modification in samples from atherosclerotic plaques. The presence of MDA 
and HNE adducts and the presence of oxLDL was reported in atheroma tissue by 
immunocytochemistry with antibodies against HNE, MDA and copper-oxidized LDL [53]. The binding 
was found to be specific for the lipid-rich region of the atherosclerotic lesion and this pattern was 
maintained across the different antibodies [53], consistent with the expected localization of the 
oxidized LDL. Several other groups also reported similar results using anti-HNE-LDL antibodies [126], 
OB/04 and OB/09 antibodies against oxLDL [61], an autoantibody against MDA-LDL [113], or using 
E06 and an antibody against MDA-LDL [127].  A review from 2000 summarized additional 
identifications of different advanced lipoxidation end-products found in atherosclerotic lesions, 
including MDA-lysine [34], HNE-lysine [33,34], and levuglandin E2 [128], which were analysed by 
both immunohistochemical and chemical techniques [129]. Antibodies raised against less studied 
aldehydes have also been tested in tissue from atherosclerotic lesions: the antibodies developed 
against HHE-histidine adducts [46] and HPNE-lysine adducts [59], which were shown to recognize 
copper-oxidized LDL, were also used to identify the presence of these adducts in human 
atherosclerotic aorta. An antibody to 4-HDDE-protein adducts showed increased staining in 
abdominal aorta of a cardiovascular patient with atherosclerosis and versus aorta from a healthy 
normotensive 41-year-old male, with no apparent atherosclerosis [60]. Thus despite the strong focus 
on smaller aldehyde adducts [130], evidence is emerging that other adducts also occur in disease, 
and may become useful markers in the future. 
Anti-HNE antibodies have also been used to demonstrate that HNE-treated LDL could 
promote the HNE modification of other proteins, such as HSP60, a protein that is a target of 
autoimmune adaptive responses, and in its modified form a ligand to scavenger receptors alongside 
oxidized LDL, suggesting a synergetic effect in the progression of atherosclerosis [131]. The 
mechanisms by which this happens are not well understood, but it is possible that HNE treatment 
results in solubilization of HNE molecules in the LDL particles, and can then modify HSP60 when cells 
are treated with HNE-LDL. Another option is that as Michael additions are reversible, HNE bound to 
the ApoB100 in HNE-LDL could be released and modify other proteins. 
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The development of a well-validated ELISA assay to detect oxidized phospholipids on ApoB-
100 containing LDL, using the E06 antibody, has enabled a substantial number of studies on the 
presence of oxidized phospholipids on LDL particles with several different cardiovascular diseases 
(CVD), mostly carried out by the groups of Tsimikas and Witztum [132]. For example, a 
reclassification of cardiovascular event in subjects from the Bruneck study followed over 15 years, 
which reported that the highest tertile of OxPL/ApoB was associated with higher risk of 
cardiovascular disease and stroke [133]. A study of stable subjects with coronary artery disease 
showed that oxidized phospholipids on ApoB-100 (oxPL-apoB) and plasminogen (oxPL-PLG) in 
plasma correlated positively with D-dimer, an end product of fibrin degradation that indicates a pro-
thrombotic state [134]. The relationship of oxPLs in Lp(a) to calcific aortic valve disease (CAVD) has 
also been investigated in the Copenhagen General population study, and showed that oxPL-apoB, 
oxPL-apo(a) and lipoprotein(a) levels all associated with risk of CAVD, suggesting that they may be 
causal risk factors for the condition [135].  These are recent studies that expand the earlier work 
reviewed in [132]. The simplicity, high-throughput and easy analysis of results of this assay makes it 
suitable for clinical studies, and although the technique does not give residue-specific information 
on the sites of lipoxidation, knowing the association with these pathologies should promote more 
detailed research on these modifications.  
Mass spectrometry techniques to detect lipoxidation markers have already been used to 
study cardiovascular disease and atherosclerosis. The Uchida group used a targeted LC-MSMS to 
identify an rLPP adduct, N-(8-carboxyoctanyl)lysine (COL), in oxidized LDL. They applied this method 
to investigate its occurrence in sera from atherosclerosis-prone mice as well as from patients with 
hyperlipidemia, and found that the modification was specifically associated with the lipoprotein 
fraction of the sera. A significantly higher amount of COL was detected in both disease conditions 
compared with the controls [72]. It was interesting that in hyperlipidemic humans, the COL levels 
were tightly clustered while the healthy controls showed more variability, whereas mice it was the 
other way round. Despite the relatively small patient and animal numbers, this study shows the 
potential of MS analysis for novel biomarker discovery. 
The detection of autoantibodies against known lipoxidation adducts, namely MDA, MAA, 
MDA-LDL, and MAA-LDL, has been used to evaluate their potential as biomarkers of atherosclerosis 
[133,136,137]. The MAA-protein adducts specifically were previously shown to be present in aortic 
tissue of rabbits on a high fat diet[138] and atherosclerotic rats [139], and led to an innate and 
acquired immune response, provoking the production of antibodies against it. One study developed 
an ELISA assay capable of binding the anti-MAA and anti-MAA-LDL antibodies from the plasma of 
human patients with non-obstructive coronary artery disease (CAD), acute myocardial infarction and 
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obstructive multi-vessel CAD [136]. While the data for the MDA-LDL and MAA-LDL adducts did not 
show a significant difference between the different conditions, which is consistent with published 
results from other groups [133,137], the results on the circulating anti-MAA IgG, IgM and IgA 
antibodies showed a significant increase in the diseased states when compared with the controls. 
The IgG/IgM/IgA profile between the different conditions also showed variability, information that 
could be used as a potential biomarker. 
 Other conditions besides atherosclerosis have also been subject of lipoprotein lipoxidation 
studies.  One study investigated the association between systemic lupus erythematosus (SLE) and 
both arterial and renal disease [140]. SLE is an autoimmune condition more prevalent in women, 
known to be linked with an early onset of atherosclerosis. The group looked at the presence of 
oxidized LDL using the E06 antibody, and determined the levels of autoantibodies against oxLDL, 
MDA-LDL and cardiolipin in patients with SLE. The results showed an increase of the E06 binding 
levels in the patients with the condition compared with the controls, and the levels of 
autoantibodies against oxLDL, MDA-LDL and cardiolipin were also significantly increased in the 
patients with SLE. It was suggested that the results obtained and the prevalence of premature 
atherosclerosis can relate to excess lipid peroxidation as playing an important role in SLE [140]. 
Antibodies against MDA-LDL and HNE-LDL were also used to stain multiple sclerosis plaques at 
different stages of disease, and these showed a localization of staining on the foam cells present 
[109], suggesting that the plasma LDL that enters the parenchyma in multiple sclerosis plaques could 
be oxidized in situ, leading to the development of foam cells. There has also been much interest in 
the occurrence of lipoxidation in neurodegenerative diseases such as Alzheimer’s disease; while 
extensive work has been done on detection of a variety of rLPP-protein adducts [141–143], there is 
less evidence for specific modifications of lipoproteins in these conditions, although it has been 
reported that ApoA-I is highly oxidatively modified and particularly susceptible to modification by 
HNE in several neurodegenerative diseases. This may cause increased levels of tumor necrosis 
factor- (TNF-) that can cross the blood-brain barrier and can contribute to neuronal death [144]. 
 The identification and study of lipoxidation adducts ex vivo has opened doors to a new field, 
the study of possible inhibitors, which could be used in the therapeutics field. One study that 
exemplifies this is by Onorato et al. They reported the use of pyridoxamine, a known inhibitor of 
AGEs, already used in clinical studies with diabetic subjects, as an inhibitor of protein modification by 
CML and CEL, MDA and HNE, both in arachidonate-treated RNase, and in copper oxidized LDL [68]. 
Similarly, glucosamine has also been studied as an inhibitor of lipid peroxidation and lipoxidation on 
osteoarthritis, using both an in vitro model of chondrocyte degradation by lipid peroxidation and 
human LDL samples [48]. Immunoblot assays were used to assess protein oxidation and adduct 
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formation, alongside a TBARS assay, to measure MDA formation. Their findings showed a 
concentration-dependent decrease of MDA production, and inhibition of protein modification, 
suggesting that glucosamine might have a protective role, in line with other published studies that 
show its role as a new antioxidant [145]. There has also been ongoing interest in carnosine and its 
derivatives over several years, as it is well established that it can react with several aldehydes 
including MDA, methylglyoxal, HNE, and acetaldehyde, which is thought to contribute to its 
protective functions [146–148]. While the use of carnosine itself presents some limitations, recent 
work has led to the development of (2S)-2-(3-amino propanoylamino)-3-(1H-imidazol-5-yl)propanol 
(carnosinol), which is a derivative of carnosine with improved oral bioavailability and resistance to 
carnosinases [74,149,150]. The compound was tested in both rat and mouse models of diet-induced 
obesity and metabolic syndrome, and was found to reduce HNE adduct formation in liver and 
skeletal muscle, while also improving typical symptoms of metabolic syndrome, namely 
dyslipidemia, insulin resistance, steatohepatitis and inflammation. Although as yet these scavenging 
compounds have not been tested specifically with lipoproteins, the likelihood is that formation of 
adducts will also be attenuated, although the non-polar environment may reduce the effectiveness. 
Another compound group, the kavalactones (including kawain, methystycin and dihydromethysticin) 
has been identified as both advanced glycation and lipid peroxidation inhibitors. The latter was 
shown by the inhibition of TBArS formation in LDL and linoleic acid, which, in conjunction with its 
metal chelating properties, indicate a possible indirect inhibition of ALEs formation [151]. 
A somewhat different strategy has been developed by Nankar and Pande [152].  They 
synthesized 11 peptides from conserved regions of human ApoE, which is known to have oxPL 
binding activity. The peptides showed differential oxPL binding and native PL binding, and those that 
bound exclusively to the ox-PLs also were able to inhibit IL-8 secretion in human blood, thus 
demonstrating anti-inflammatory activity.  
 
6. Summary and perspectives  
In conclusion, interest in the formation of rLPP adducts with lipoproteins is growing steadily, 
with many publications reporting their formation in a wide variety of conditions. Lipoproteins are 
already considered as biomarkers in some conditions, but understanding of lipoxidative 
modifications will add an additional layer of specificity to improve their value.  Development of a 
range of antibodies has been invaluable for immunohistochemistry, and has provided substantial 
evidence for formation of certain adducts in vivo, frequently with increased levels in inflammatory 
diseases. The current limitation is that antibodies are only available for a relatively small number of 
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rLPP adducts, compared to the number that exist and have been found by other methods, but work 
is ongoing to improve this. Despite the challenging nature of the analysis, improvements in mass 
spectrometry technologies are yielding very detailed qualitative and quantitative information on the 
sites of modification, which is important both in understanding the biological effects of the 
modifications, and designing therapeutic interventions. It is essential to appreciate the 
complementary nature of the different techniques, in terms of the types of information that they 
offer. It is also worth noting that currently the interest in rLLPs and lipoxidation is largely skewed 
towards pathology, as such modifications have widely been considered as deleterious, but the 
concept of rLPPs as signaling molecules with a role in hormesis is gaining favor. Ultimately, the 
understanding in this area will depend on the sensitivity of methods for detecting the modifications, 
and specific inhibitors to unravel their outcomes. 
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Figure 1. Structures of the reactive lipid peroxidation products (rLPPs) reported to form adducts 
with lipoproteins. Note that Ne-(3-methylpyridinium) is shown as the lysine adduct form. 
 
Figure 2. Structures of common advanced lipoxidation end products (ALEs) or adducts detected on 
lipoproteins. The type of rLPP causing adduct formation is writtten in bold above the structure(s) 
and the resulting adduct names are give in plain text below. Trans-HHP-lysine is trans-Ne3-[(hept-1-
enyl)-4-hexylpyridinium]lysine. 
 
Figure 3. The most used techniques for the analysis of lipozidized lipoproteins, and their 
advantages and disadvantages. TBArs, thiobarbituric acid reactive substance assay; TNBS, 2,4,6-
trinitrobenzene sulfonic acid; UV, Ultraviolet; IHC, Immunohistochemistry; ELISA, enzyme-linked 
immunosorbent assay; LC-MS, liquid chromatography-mass spectrometry; GC-MS, Gas 
chromatography-mass spectrometry. 
 
Figure 4. Scheme of the amino acid location of several types of modifications found in different 
apolipoproteins. The abbreviated modifications are shown in bold and given in full as follows: 
CHa,Cyclic hemiacetal adduct; FDP-Lys, Ne-(3-formyl-3, 4-dehydropiperidino)lysine (formed by MA-
MA); HF, 2,3-dihydrofuran adduct; HNE, 4-Hydroxy-2-nonenal; HODA-PL, 9-hydroxy-12-oxo-10-
dodecenoic acidb; HOHA-PLb, 4-hydroxy-7-oxo-5-heptenoic acid; HOOA-PLb, 5-hydroxy-8-oxo-6-
octenoic acid; 3-HOSCA, 3β-hydroxy-5-oxo-5,6-secocholestan-6-al; KAa, Ketoamide adduct; KODA-
PLb, 9-keto-12-oxo-10-dodecenoic acid; KOOA-PLb, 5-keto-8-oxo- 6-octenoic acid; KOHA-PLb, 4-keto-
7-oxo-5-heptenoic acid; MA, Michael Addition; MP-Lys, Ne-(3-methylpyr-idinium)lysine (formed by 
MA-SB); OV-PLb, 5-oxovaleric acid; ON-PLb, 9-oxononanoic acid; POVPC, 1-palmitoyl-2-(5'-oxo-
valeroyl)-sn-glycero-3-phosphocholine; PONPC, 1-palmitoyl-2-(9-oxo-nonanoyl)-sn-glycero-3-
phosphocholine; SB, Schiff‘s base adduct. a CH and KA forms are indistinguishable by LC-MS. b These 
adducts were detected by aminolysis and assumed to be derived from esters of lysophospholipids. 
This figure was prepared using data obtained from references [67,77,78,82,86,87]. 
 
Figure 5. Physiological effects of lipoxidized lipoproteins, with consequences for the immune 
system, inflammation, apoptosis and HDL function. (1) Oxidized LDL stimulates the production of 
antibodies against itself and oxidized phospholipids, that can be recognized by the immune system; 
(2) oxLDL and MDA-LDL bind to scavenger receptors, leading to their internalization and formation of 
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foam cells; oxPC-Lp(a) promotes the expression of IL-8 by macrophages, increasing inflammation; (3) 
HNE-LDL leads to apoptosis by both inhibition the ubiquitin proteasome pathway and by 
modification of tyrosine kinase receptors, leading to their inhibition; (4) Acrolein-HDL inhibits the 
increase of HDL caused by 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), and HDL uptake 
and disassembly due to the decreased binding to the LDL receptor. 
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Highlights 
• Lipoproteins can be modified by reactive Lipid Peroxidation Products (rLPPs) 
• Lipoprotein lipoxidation is known to occur in several inflammatory diseases 
• Biochemical, immunochemical and mass spectrometry methods can detect rLPP adducts 
• Due to higher information output, MS can facilitate localization of modifications  
• Antibodies against some rLPPs have been used to identify lipoxidation in vivo 
 
 
